App Store

Google Play

DK - Details page - Device banner - 894x1036

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

Lyt når som helst, hvor som helst 

a16z Bio + Health

Andreessen Horowitz

A myriad of AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health, a podcast by a16z Bio + Health and hosted by Kris Tatiossian and Olivia Webb, dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders, operators, and investors Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, along with distinguished guests like Mark Cuban, Greg Verdine, Fei-Fei Li, and Suchi Saria, as they explore the intricacies of these technological advancements and how they can be built and effectively delivered. Together, we can rewrite the script. Welcome to Raising Health.

Raising Health

In this episode, Matt Wilsey joins Jorge Conde to share the profound personal story of his daughter Grace's diagnosis with NGLY1 deficiency and how it catalyzed his journey to founding a biotech startup, Grace Science, aimed at developing a cure for his daughter’s condition.

Matt emphasizes the importance of strategic partnerships, like his collaboration with Nobel laureate Carolyn Bertozzi, and sheds light on the search for gene therapies for rare diseases. 

Check out our previous episode with Carolyn Bertozzi here.

Rare Disease, Big Impact with Matt Wilsey

Jeff Margolis, founder of TriZetto, joins Julie Yoo, a16z Bio + Health general partner, to share the journey of building an iconic company in healthcare infrastructure. From the early days of managed care to creating a three-pronged platform uniting computing power, software, and data analytics, Jeff reflects on TriZetto’s groundbreaking model that reshaped payer-provider transactions and set industry standards. Together, they also delve into the strategic importance of scaling through acquisitions, aligning with industry standards, and crafting innovative pricing models.

Lessons from Healthcare Infrastructure Pioneers with Jeff Margolis

Hippocratic AI cofounder and CEO Munjal Shah joins a16z Bio + Health general partner Julie Yoo to explore the incredible potential of generative AI in transforming healthcare delivery. Together, they discuss the emerging "voice renaissance" in healthcare, the nuances of designing safe and empathetic AI interactions, and how Hippocratic AI is addressing safety concerns with innovations like multi-LLM architecture and rigorous training with thousands of nurses. 

This episode also discusses a shift toward viewing AI tools as an opportunity for healthcare "super staffing," and strategies for integrating AI into complex healthcare systems.

Super Staffing in Healthcare with Munjal Shah

Rajaie Batniji, MD, PhD, Afia Asamoah, JD, and Sanjay Basu, MD, PhD, cofounders of Waymark, join Vineeta Agarwala, MD, PhD, a16z Bio + Health general partner, to discuss their transformative approach to Medicaid care delivery. This episode dives into their rising risk signal prediction framework, where cutting-edge machine learning predicts patient needs and enables community-based care teams to reduce preventable ER visits and improve health outcomes at scale. 

The team recently published their real-world results—including a 23% reduction in unnecessary acute care—in the New England Journal of Medicine Catalyst.

Additional resources:

Supporting Rising-Risk Medicaid Patients Through Early Intervention • , NEJM Catalyst
The Body Economic • : Why Austerity Kills, by David Stuckler and Sanjay Basu

Scaling Medicaid Innovation with Afia Asamoah, Rajaie Batniji, and Sanjay Basu

Alexander Saint-Amand, cofounder and CEO of Topography, reflects on his journey from leading Gerson Lehrman Group (GLG), a pioneer in expert networks, to tackling systemic barriers in clinical trials at his current company, Topography. Inspired by personal experiences, Alexander’s mission centers on democratizing access to clinical research by transforming community-based practices into thriving hubs for trials. Alongside a16z Bio + Health general partner Julie Yoo, he discusses the pervasive challenges in enrollment, physician participation, and the inefficiencies plaguing the current model.

Alexander also talks through Topography's hybrid approach—combining technology, services, and AI—and its potential to lower the barrier to entry for providers, improving patient access.

Transforming Clinical Trials with Alexander Saint-Amand

Ankit Jain, CEO and cofounder of Infinitus Systems, Inc, joins Julie Yoo, a16z Bio + Health general partner, to discuss Infinitus's work in solving one of healthcare's most pressing challenges: workforce shortages. Leveraging LLMs and AI voice agents, Infinitus automates repetitive tasks, such as benefits verification and prior authorization, freeing up human talent for higher-value roles. Ankit reflects on the company’s journey—from early proof-of-concept calls to scaling over five million patient-centric interactions—and shares their approach to mitigating the risks of AI errors through layered guardrails.

 

More in "The Opportunity for Healthcare in a Post-LLM World":

Super Staffing in Healthcare with Munjal ShahTransforming Clinical Trials with Alexander Saint-Amand
Plus:

 • Learn more about 
a16z Bio+Health • Learn more about & Subscribe to 
Raising Health • Find a16z Bio+Health on 
LinkedIn • Find a16z Bio+Health on 
X

Voice AI: Solving Healthcare's Workforce Challenges with Ankit Jain

This new show, from the same team that produces the popular a16z Podcast, will be all about how biology today is where technology was 50 years ago: on the precipice of revolutionizing our world in ways we are only just beginning to appreciate.

Through conversations with scientists, builders, entrepreneurs, and leaders at the intersection of science, tech, and business, the Bio Eats World team, including hosts Hanne Winarsky and Lauren Richardson, examine how biology—and our new ability to engineer it—is going to revolutionize our future, and in ways we are only just beginning to imagine.

Introducing "Bio Eats World"

with @LauraDeming, @kpfortney, @vijaypande, and @omnivorousread

Welcome to the first episode of Bio Eats World, a brand new podcast all about how biology is technology. Bio is breaking out of the lab and clinic and into our daily lives—on the verge of revolutionizing our world in ways we are only just beginning to imagine.

In this episode, we talk all about the science of aging. Once a fringe field, aging research is now entering a new phase with the first clinical trials of aging-related drugs. As the entire field shifts into this moment of translation, what have we learned? What are the basic approaches to developing aging-related drugs? How is studying aging helping us understand diseases like cancer and Alzheimer's—and increasing the amount of time we are healthy—today? 

In this conversation, Laura Deming, founder of The Longevity Fund; Kristen Fortney, co-founder of BioAge, a clinical-stage company focused on finding drugs to extend healthspan; Vijay Pande, general partner at a16z; and host Hanne Winarsky discuss the entire arc of aging science from one genetic tweak in a tiny worm to changing a whole paradigm of healthcare delivery.

The Biology of Aging

In Bio Eats World's Journal Club episodes, we discuss groundbreaking research articles, why they matter, what new opportunities they present, and how to take these findings from paper to practice. In this episode, Stanford Professor Carolyn Bertozzi and host Lauren Richardson discuss the article "Lysosome-targeting chimaeras for degradation of extracellular proteins" by Steven M. Banik, Kayvon Pedram, Simon Wisnovsky, Green Ahn, Nicholas M. Riley & Carolyn R. Bertozzi, published in Nature584, 291–297 (2020).

Many diseases are caused by proteins that have gone haywire in some fashion. There could be too much of the protein, it could be mutated, or it could be present in the wrong place or time. So how do you get rid of these problematic proteins? Dr. Bertozzi and her lab developed a class of drugs -- or modality -- that in essence, tosses the disease-related proteins into the cellular trash can. While there are other drugs that work through targeted protein degradation, the drugs created by the Bertozzi team (called LYTACs) are able to attack a set of critical proteins, some of which have never been touched by any kind of drug before. Our conversation covers how they engineered these new drugs, their benefits, and how they can be further optimized and specialized in the future.

Journal Club: Degrading Drugs for Problematic Proteins

with @JorgeCondeBio, @JLimMD, @AmerCancerCEO, and @omnivorousread

In this episode of Bio Eats World, we explore all the major revolutions in cancer treatment across the history of medicine—and what’s coming next. Hanne Winarsky delves into the past and future of the fight against cancer with Gary Reedy, CEO of the American Cancer Society; Jonathan Lim, CEO of Erasca, a biotech company with the mission of erasing cancer; and Jorge Conde, a16z general partner. The conversation spans not only the history of cancer treatment from the early days of surgery and the first radiology treatment (with an x-ray!), but also the fundamental nature of cancer—its origins, progressions, and how to stop it; the birth of precision genetic medicine and targeted therapies; our most powerful tools today (both low and high tech); and finally, the coming new tools and revolutions at the very cutting edge of cancer treatment.

Revolutions in Cancer Treament—Past, Present, and Future

Vijay Pande, PhD, founding partner of a16z Bio + Health, joins Derrick Harris, host of the AI + a16z podcast. Together, they discuss how computer science has subsumed biotech.

AI + a16z with Vijay Pande

Lyt når som helst, hvor som helst

Other podcasts you might like ...